CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial
DOI 10.1055/s-0036-1580798
Bibliografische Angaben
Nachweis in CareLit
Autor:innenW Kern, T Wehrhahn, C Le Roux, A Astrup, K Fujioka, F Greenway, D Lau, L Van Gaal, R Violante Ortiz, J Wilding, X Pi-Sunyer, T Skjøth, L Shapiro Manning
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
This 3-year trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet and exercise (D&E), in delaying the onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities. Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo; all were advised on D&E. Efficacy data are observed means, with last obs…
Zitieren
Zitierempfehlung
W Kern, T Wehrhahn, C Le Roux, A Astrup, K Fujioka, F Greenway, D Lau, L Van Gaal, R Violante Ortiz, J Wilding, X Pi-Sunyer, T Skjøth, L Shapiro Manning (2016) Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580798
Mit CareLit weiterarbeiten